Cargando…
Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2
In Alzheimer’s disease (AD) more than 50% of the patients are affected by capillary cerebral amyloid-angiopathy (capCAA), which is characterized by localized hypoxia, neuro-inflammation and loss of blood-brain barrier (BBB) function. Moreover, AD patients with or without capCAA display increased ves...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684660/ https://www.ncbi.nlm.nih.gov/pubmed/38016947 http://dx.doi.org/10.1038/s41419-023-06316-8 |
_version_ | 1785151453277454336 |
---|---|
author | Vacondio, D. Nogueira Pinto, H. Coenen, L. Mulder, I. A. Fontijn, R. van het Hof, B. Fung, W. K. Jongejan, A. Kooij, G. Zelcer, N. Rozemuller, A. J. de Vries, H. E. de Wit, N. M. |
author_facet | Vacondio, D. Nogueira Pinto, H. Coenen, L. Mulder, I. A. Fontijn, R. van het Hof, B. Fung, W. K. Jongejan, A. Kooij, G. Zelcer, N. Rozemuller, A. J. de Vries, H. E. de Wit, N. M. |
author_sort | Vacondio, D. |
collection | PubMed |
description | In Alzheimer’s disease (AD) more than 50% of the patients are affected by capillary cerebral amyloid-angiopathy (capCAA), which is characterized by localized hypoxia, neuro-inflammation and loss of blood-brain barrier (BBB) function. Moreover, AD patients with or without capCAA display increased vessel number, indicating a reactivation of the angiogenic program. The molecular mechanism(s) responsible for BBB dysfunction and angiogenesis in capCAA is still unclear, preventing a full understanding of disease pathophysiology. The Liver X receptor (LXR) family, consisting of LXRα and LXRβ, was reported to inhibit angiogenesis and particularly LXRα was shown to secure BBB stability, suggesting a major role in vascular function. In this study, we unravel the regulatory mechanism exerted by LXRα to preserve BBB integrity in human brain endothelial cells (BECs) and investigate its role during pathological conditions. We report that LXRα ensures BECs identity via constitutive inhibition of the transcription factor SNAI2. Accordingly, deletion of brain endothelial LXRα is associated with impaired DLL4-NOTCH signalling, a critical signalling pathway involved in vessel sprouting. A similar response was observed when BECs were exposed to hypoxia, with concomitant LXRα decrease and SNAI2 increase. In support of our cell-based observations, we report a general increase in vascular SNAI2 in the occipital cortex of AD patients with and without capCAA. Importantly, SNAI2 strongly associated with vascular amyloid-beta deposition and angiopoietin-like 4, a marker for hypoxia. In hypoxic capCAA vessels, the expression of LXRα may decrease leading to an increased expression of SNAI2, and consequently BECs de-differentiation and sprouting. Our findings indicate that LXRα is essential for BECs identity, thereby securing BBB stability and preventing aberrant angiogenesis. These results uncover a novel molecular pathway essential for BBB identity and vascular homeostasis providing new insights on the vascular pathology affecting AD patients. [Image: see text] |
format | Online Article Text |
id | pubmed-10684660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-106846602023-11-30 Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2 Vacondio, D. Nogueira Pinto, H. Coenen, L. Mulder, I. A. Fontijn, R. van het Hof, B. Fung, W. K. Jongejan, A. Kooij, G. Zelcer, N. Rozemuller, A. J. de Vries, H. E. de Wit, N. M. Cell Death Dis Article In Alzheimer’s disease (AD) more than 50% of the patients are affected by capillary cerebral amyloid-angiopathy (capCAA), which is characterized by localized hypoxia, neuro-inflammation and loss of blood-brain barrier (BBB) function. Moreover, AD patients with or without capCAA display increased vessel number, indicating a reactivation of the angiogenic program. The molecular mechanism(s) responsible for BBB dysfunction and angiogenesis in capCAA is still unclear, preventing a full understanding of disease pathophysiology. The Liver X receptor (LXR) family, consisting of LXRα and LXRβ, was reported to inhibit angiogenesis and particularly LXRα was shown to secure BBB stability, suggesting a major role in vascular function. In this study, we unravel the regulatory mechanism exerted by LXRα to preserve BBB integrity in human brain endothelial cells (BECs) and investigate its role during pathological conditions. We report that LXRα ensures BECs identity via constitutive inhibition of the transcription factor SNAI2. Accordingly, deletion of brain endothelial LXRα is associated with impaired DLL4-NOTCH signalling, a critical signalling pathway involved in vessel sprouting. A similar response was observed when BECs were exposed to hypoxia, with concomitant LXRα decrease and SNAI2 increase. In support of our cell-based observations, we report a general increase in vascular SNAI2 in the occipital cortex of AD patients with and without capCAA. Importantly, SNAI2 strongly associated with vascular amyloid-beta deposition and angiopoietin-like 4, a marker for hypoxia. In hypoxic capCAA vessels, the expression of LXRα may decrease leading to an increased expression of SNAI2, and consequently BECs de-differentiation and sprouting. Our findings indicate that LXRα is essential for BECs identity, thereby securing BBB stability and preventing aberrant angiogenesis. These results uncover a novel molecular pathway essential for BBB identity and vascular homeostasis providing new insights on the vascular pathology affecting AD patients. [Image: see text] Nature Publishing Group UK 2023-11-28 /pmc/articles/PMC10684660/ /pubmed/38016947 http://dx.doi.org/10.1038/s41419-023-06316-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Vacondio, D. Nogueira Pinto, H. Coenen, L. Mulder, I. A. Fontijn, R. van het Hof, B. Fung, W. K. Jongejan, A. Kooij, G. Zelcer, N. Rozemuller, A. J. de Vries, H. E. de Wit, N. M. Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2 |
title | Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2 |
title_full | Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2 |
title_fullStr | Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2 |
title_full_unstemmed | Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2 |
title_short | Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2 |
title_sort | liver x receptor alpha ensures blood-brain barrier function by suppressing snai2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684660/ https://www.ncbi.nlm.nih.gov/pubmed/38016947 http://dx.doi.org/10.1038/s41419-023-06316-8 |
work_keys_str_mv | AT vacondiod liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2 AT nogueirapintoh liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2 AT coenenl liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2 AT mulderia liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2 AT fontijnr liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2 AT vanhethofb liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2 AT fungwk liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2 AT jongejana liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2 AT kooijg liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2 AT zelcern liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2 AT rozemulleraj liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2 AT devrieshe liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2 AT dewitnm liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2 |